inPractice® - Implantable, Intravaginal, and Intrauterine Contraceptives

All combined hormonal contraceptive methods and intrauterine devices are listed as Category 1 (no restriction for use) for women at high risk for HIV or with HIV or AIDS by the CDC Medical Eligibility Criteria for Contraceptive Use^{[Tepper 2020]} Efavirenz may decrease etonogestrel and levonorgestrel levels attained from implants^{[DHHS Perinatal; ref:Leticee 2012; Scarsi 2016]}
Cobicistat may increase estrogen and progestin levels^{[Nanda 2017]}
Ritonavir may decrease or increase progestin levels depending on the specific contraceptive used^{[Nanda 2017]}